MYRIAM FRIAS: Open Payments
NPI 1730742388 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,588 in 77 payments from 12 companies in 2025. Trend: 2023 $672 · 2024 $1,321 · 2025 $2,588
Food & beverage: $2,504Education: $84
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $1,049 |
| Janssen Biotech, Inc. | 9 | $401 |
| Novo Nordisk Inc | 4 | $254 |
| Madrigal Pharmaceuticals | 4 | $200 |
| Ipsen Biopharmaceuticals, Inc | 6 | $167 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $102 |
| Neurocrine BioSciences, Inc. | 1 | $100 |
| Ardelyx, Inc. | 5 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $86 |
| Lilly USA, LLC | 1 | $76 |
Products named: SKYRIZI, TREMFYA, Wegovy, RINVOQ, REZDIFFRA, XIFAXAN, Bylvay, IBSRELA.
Industry payments across TX — which companies pay providers there.
